Press Releases

Shockwave Medical Reports Second Quarter 2019 Financial Results

SANTA CLARA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2019.

Recent Highlights

  • Recognized revenue of $10.0 million for the second quarter of 2019, representing a 339% increase over the second quarter of 2018
  • Appointed industry veterans Keith Dawkins M.D. to Chief Medical Officer and Hajime Tada as General Counsel
  • Crossed the 100-patient enrollment threshold in CAD III, the Company’s U.S. coronary IDE trial
  • Had data from Company’s CAD II European Registry accepted for presentation at Transcatheter Cardiovascular Therapeutics (TCT) 2019, to be held in September
  • Completed the move of production facilities to the Santa Clara site, more than doubling capacity

“We continue to be encouraged by our results thus far in 2019 – both financially and operationally - as our organization continues to improve execution on all fronts,” said Doug Godshall, President and Chief Executive Officer. “The balanced mix of our products, both geographically and clinically, combined with the strong interest from physicians, speaks to the versatility of our IVL technology and its ability to help patients with complex calcified cardiovascular disease.  Our progress operationally, clinically and financially is encouraging and gives us confidence to continue expanding and enhancing our team.”

Second Quarter 2019 Financial Results
Revenue for the second quarter of 2019 was $10.0 million, an increase of $7.7 million, or 339%, compared to the second quarter of 2018. The growth was primarily driven by the increased sales of our M5 IVL catheter in the U.S. and the growth of our C2 international business.

Gross profit for the second quarter of 2019 was $5.9 million compared to $1.1 million for the second quarter of 2018. The gross margin percentage for the second quarter of 2019 increased to 59% compared to 48% in the second quarter of 2018, driven primarily by increased efficiencies and higher production volume, which improved the absorption of fixed costs.

Operating expenses were $17.1 million for the second quarter of 2019 compared to $11.3 million in the corresponding prior year period, an increase of 52%, primarily driven by commercial expansion, increased spend on clinical programs and costs associated with being a public company.

Net loss was $10.6 million in the second quarter of 2019, as compared to $10.1 million in the corresponding period of the prior year. Net loss per share was $0.38 in the second quarter of 2019.

Cash, cash equivalents and short-term investments totaled $125.1 million as of June 30, 2019.

2019 Financial Guidance
Shockwave Medical projects revenue for the full year 2019 to range from $38 million to $40 million, which represents 210% to 226% growth over the company’s prior year revenue.

Conference Call
Shockwave Medical will host a conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Monday, August 5, 2019 to discuss its second quarter 2019 financial results. The call may be accessed through an operator by calling (866) 795-9106 for domestic callers and (470) 495-9173 for international callers using conference ID number 2399907. A live and archived webcast of the event will be available at

About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated by establishing a new standard of care with Intravascular Lithotripsy (IVL) technology. The company’s differentiated and proprietary IVL approach to calcium modification uses sonic pressure waves to safely and effectively fracture problematic calcium throughout the cardiovascular system in a wide and growing number of applications. For more information, visit

Forward-Looking Statements
This press release contains statements relating to Shockwave’s expectations, projections, beliefs, and prospects (including statements regarding Shockwave’s financial and business outlook), which are “forward-looking statements” within the meaning of the federal securities laws and by their nature are uncertain. Words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plans,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability; failure to effectively market existing products; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; the inability to attain coverage and adequate reimbursement for procedures using our products; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including under the section entitled “Risk Factors” in our prospectus dated March 6, 2019. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

Investor Contact:
Debbie Kaster, Gilmartin Group

Balance Sheet Data
(In thousands)

June 30,
December 31,
Cash and cash equivalents $ 41,924 $ 39,643
Short-term investments 83,213
Accounts receivable, net 5,242 2,850
Inventory 8,291 5,131
Prepaid expenses and other current assets 1,953 1,112
Total current assets 140,623 48,736
Operating lease right-of-use asset 2,398
Property and equipment, net 3,244 2,619
Other assets 542 2,066
TOTAL ASSETS $ 146,807 $ 53,421
Accounts payable $ 2,216 $ 1,487
Term notes, current position 5,000 1,667
Accrued liabilities 7,378 6,217
Lease liabilities, current portion 806
Total current liabilities 15,400 9,371
Lease liability, noncurrent portion 1,732
Term notes, noncurrent portion 10,262 13,383
Convertible preferred stock warrant liability 313
Other liabilities 136
Convertible preferred stock 152,806
Preferred stock
Common stock 28 2
Additional paid-in capital 269,582 4,275
Accumulated other comprehensive loss 75
Accumulated deficit (150,272 ) (126,865 )

Statement of Operations Data
(In thousands, except share and per share data)

Three Months Ended
June 30,
Six Months Ended
June 30,
2019 2018 2019 2018
Product revenue $ 10,012 $ 2,279 $ 17,282 $ 3,601
Operating expenses:
Cost of product revenue 4,133 1,179 7,205 1,973
Research and development 6,926 5,530 14,410 11,046
Sales and marketing 6,961 4,372 12,831 7,810
General and administrative 3,245 1,392 6,247 2,768
Total operating expenses 21,265 12,473 40,693 23,597
Loss from operations (11,253 ) (10,194 ) (23,411 ) (19,996 )
Interest expense (250 ) (40 ) (495 ) (58 )
Change in fair value of warrant liability 10 (609 ) 51
Other income, net 913 138 1,133 323
Net loss before taxes (10,590 ) (10,086 ) (23,382 ) (19,680 )
Income tax provision 18 21 25 21
Net loss $ (10,608 ) $ (10,107 ) $ (23,407 ) $ (19,701 )
Net loss per common share, basic and diluted $ (0.38 ) $ (5.79 ) $ (1.25 ) $ (11.42 )
Shares used in computing net loss per share, basic and diluted 28,002,887 1,745,499 18,735,307 1,725,414

Logo 1.png

Source: Shockwave Medical, Inc.

Share this page:

Ready to Make Waves with Shockwave Medical?

Looking for careers? Click here.